Compare MNY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | SCYX |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | Singapore | United States |
| Employees | 240 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 37.0M |
| IPO Year | N/A | 2014 |
| Metric | MNY | SCYX |
|---|---|---|
| Price | $0.92 | $5.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.00 | $3.00 |
| AVG Volume (30 Days) | 11.2K | ★ 231.6K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.57 |
| 52 Week High | $2.40 | $5.62 |
| Indicator | MNY | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 65.23 |
| Support Level | $0.78 | $0.65 |
| Resistance Level | $1.03 | $5.62 |
| Average True Range (ATR) | 0.05 | 0.45 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 0.00 | 83.08 |
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.